Showing results (41-50 of 177) with videos related to
Sort By:
Pageof 18
PEC Innovation|May 22, 2023
Development of a novel measure of advanced cancer patients' perceived utility of secondary germline findings from tumor genomic profilingJada G Hamilton, Ibrahim H Shah, Caroline Salafia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2010
Genome-wide association studies of cancerZsofia K Stadler, Peter Thom, Mark E Robson, et al.Familial Cancer|March 11, 2014
Mosaic partial deletion of the PTEN gene in a patient with Cowden syndromeErin E Salo-Mullen, Jinru Shia, Isaac Brownell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2008
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessmentRobin T Zon, Elizabeth Goss, Victor G Vogel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
BRCA mutations and risk of prostate cancer in Ashkenazi JewsTomas Kirchhoff, Noah D Kauff, Nandita Mitra, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer SusceptibilityMark E Robson, Angela R Bradbury, Banu Arun, et al.Journal of Medical Genetics|March 19, 2011
Germline PALB2 mutation analysis in breast-pancreas cancer familiesZsofia K Stadler, Erin Salo-Mullen, Nelly Sabbaghian, et al.Breast Cancer Research : BCR|December 19, 2003
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatmentMark E Robson, Pierre O Chappuis, Jaya Satagopan, et al.European Journal of Cancer (Oxford, England : 1990)|March 9, 2023
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerMark E Robson, Seock-Ah Im, Elzbieta Senkus, et al.Cancer|October 15, 2008
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007Gordon F Schwartz, Kevin S Hughes, Henry T Lynch, et al.Pageof 18